Alvotech

NASDAQ:ALVO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.55 -1.02%

-$0.04 today

Market cap
$1.62B
Beta
0.21
P/E (TTM)
-15.9
EPS (TTM)
-$0.24
52W Low $2.94High $9.94

Volume 1.56M

Average 0.65M

ALVO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

AlvotechNASDAQ: ALVO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $24.51M fell 35.8% year over year, behind the +6.8% change in trailing-twelve-month research & development. Sequentially, it fell 38.2% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.

Context

  • Research & development amounted to 31.4% of revenue in FY2025, down 3.6 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -35.8% toward the trailing-twelve-month pace of +6.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.51M-38.2% QoQ
Last fiscal yearDec 2025
$184.19M+7.5% YoY
LTMMar 2026
$170.53M+6.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.8%——
1 year+7.5%——
3-year CAGR+0.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
184.19M USD
Year-over-year change
+7.5%
4-year CAGR
-0.9%

Research & Development vs competitors

How ALVO compares with its peers on the latest reported figures

  • ALVO's LTM Mar 2026 research & development of $170.53M is the 7th highest of the 11 companies compared; the peer median is $267.33M.
  • Its year-over-year change of +6.8% is the 6th highest of 10, against a peer median of +16.9%.
  • Research & development amounts to 30.5% of revenue for ALVO, versus a peer median of 7.8%.
ALVO Competitors Peer median
Research & Development for ALVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMGNAmgen Inc.LTM Jun 2026$7.64B +19.3%+16.3%20.0%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$6.46B +16.9%+24.2%41.6%
BIIBBiogen Inc.LTM Jun 2026$1.95B -19.9%-9.0%19.6%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$995M -0.7%+6.5%5.7%
OGNOrganon & Co.LTM Sep 2026$357M -11.9%-8.1%5.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$177.66M -15.0%-3.7%5.7%
ALVOAlvotechLTM Mar 2026$170.53M +6.8%+0.7%30.5%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$92.49M +20.2%+4.7%12.8%
HROWHarrow Health, Inc.LTM Mar 2026$15.36M +17.2%+61.5%5.7%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$8.48M +125.2%+24.8%9.8%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding ALVO) $267.33M+16.9%+6.5%7.8%

Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.77M83.03M91.43M489.68M586.32M
Cost of Revenue064.1M160.86M185.31M235.56M
Gross Profit36.77M18.93M(69.42M)304.37M350.76M
Gross Margin100.0%22.8%-75.9%62.2%59.8%
Research & Development191.01M180.62M210.83M171.31M184.19M
Selling, General & Admin84.13M186.74M73.04M61.45M90.95M
Operating Expenses272.23M365.38M285.44M234.73M272.56M
Depreciation & Amortization18.2M20.41M24.21M31.3M37.85M
EBITDA(18.03M)(439.8M)(493.67M)(32.28M)323.39M
EBITDA Margin-49.0%-529.7%-539.9%-6.6%55.2%
Operating Income(235.46M)(346.44M)(354.86M)69.64M78.21M
Operating Margin-640.3%-417.3%-388.1%14.2%13.3%
Interest Income19K912K4.82M4.62M198.49M
Interest Expense112.97M91.44M134.82M157.6M149.19M
Other Income / Expenses86.26M(205.21M)(296.19M)(287.21M)58.14M
Income Before Tax(149.2M)(551.65M)(651.05M)(217.56M)136.35M
Pre-Tax Margin-405.7%-664.4%-712.0%-44.4%23.3%
Income Tax Expense(47.69M)(38.07M)(99.32M)14.3M108.43M
Net Income(101.5M)(513.58M)(551.73M)(231.86M)27.92M
Net Margin-276.0%-618.6%-603.4%-47.3%4.8%
EPS (Basic)(3.25)(2.60)(2.43)(0.87)0.10
EPS (Diluted)(3.25)(2.60)(2.43)(0.87)0.10
Weighted Avg Shares31.25M197.72M227.26M267.92M279.19M
Weighted Avg Shares (Diluted)31.25M197.72M227.26M267.92M279.19M

Alvotech

NASDAQ:ALVO

Intrinsic Alpha fair value

Locked

Current Price

$4.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.